CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MT-act is developing a new drug, MT-011, targeting VASH, an enzyme linked to glaucoma and other neurodegenerative diseases. The project aims to advance this drug through preclinical development to address the unmet needs of patients suffering from normal tension glaucoma.
Glaucoma is the world's leading cause of irreverisble blindness, affecting 20 million people in Europe and the US.
Known as the Alzheimer’s of the eye, glaucoma is a neurodegenerative disorder that causes deterioration in peripheral vision.
Affected patients report ‘seeing through a black tunnel’.
Treatments to halt vision loss are available however, they are only applicable for the ‘high tension glaucoma’ subtype.
For those diagnosed with ‘normal tension', which comprises over 30% of glaucoma p…
MT ACT
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
